The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006.

scientific article published on 08 August 2011

The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/PDS.2216
P932PMC publication ID6324845
P698PubMed publication ID21823196

P50authorElaine JaffeQ19647268
Lisa J HerrintonQ91306296
P2093author name stringLiyan Liu
Oren Abramson
P2860cites workHepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel diseaseQ28285213
Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patientsQ33349390
Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990.Q33949912
Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q.Q41543854
Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprineQ44398756
Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn diseaseQ45256545
Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update.Q50600269
Infliximab, azathioprine, or combination therapy for Crohn's diseaseQ56988763
Epidemiology of the Revised European-American Lymphoma Classification subtypesQ77907591
P433issue1
P921main subjectCaliforniaQ99
hepatosplenic T-cell lymphomaQ5731794
P304page(s)49-52
P577publication date2011-08-08
P1433published inPharmacoepidemiology and Drug SafetyQ15759496
P1476titleThe incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006.
P478volume21

Reverse relations

cites work (P2860)
Q87454022Frequency and clonality of peripheral γδ T cells in psoriasis patients receiving anti-tumour necrosis factor-α therapy
Q36812503Hepatosplenic T-Cell Lymphoma: A Population-Based Study Assessing Incidence and Association With Immune-Mediated Disease
Q48160916Incidence, clinical findings, and survival of hepatosplenic T-cell lymphoma in the United States.
Q36993224PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma
Q34065549Patient preferences for surgical versus medical therapy for ulcerative colitis
Q27004241Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfalls
Q37661741TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents.
Q35072606The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model
Q33621267Use of thiopurines in inflammatory bowel disease: Safety issues

Search more.